Compare LYNX & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYNX | NKTR |
|---|---|---|
| Founded | 2018 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2026 | 1996 |
| Metric | LYNX | NKTR |
|---|---|---|
| Price | $11.60 | $37.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 15 |
| Target Price | $19.67 | ★ $133.08 |
| AVG Volume (30 Days) | 347.4K | ★ 891.5K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $307,711,000.00 |
| Revenue This Year | $35.28 | N/A |
| Revenue Next Year | $34.08 | $27.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 86.00 |
| 52 Week Low | $10.27 | $33.40 |
| 52 Week High | $14.64 | $109.00 |
| Indicator | LYNX | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 33.05 |
| Support Level | $10.49 | $35.61 |
| Resistance Level | $13.74 | $39.89 |
| Average True Range (ATR) | 0.60 | 1.62 |
| MACD | 0.12 | 1.16 |
| Stochastic Oscillator | 64.00 | 39.35 |
Lyntris Inc is a defense technology company that develops connectivity solutions for military applications. Its products consist of interconnected subsystems designed to support defense and military customers in detecting threats, making decisions, and responding to operational requirements across multi-domain environments. The company serves U.S. and allied nation military customers. Its solutions are deployed across three core missions: Maritime Domain Awareness; Air & Missile Defense; and Space ISR & Resilient Communications. Maximum revenue is derived from the Maritime Domain Awareness business, which includes solutions focused on maritime monitoring, tracking and analysis that support government and defense customers in maintaining situational awareness across maritime environments.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.